Flotek Industries, Inc.
FTKFlotek Industries, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +147.1% against a +116.1% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (75 weeks in). Underneath, the last four quarters read deteriorating — profit −100.0% year on year, and 0% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Flotek Industries, Inc. trades at $28.1, in a confirmed uptrend and 75 weeks into that stage. That is +38.3% against its own 200-day average. It sits at 65% of a 52-week range of $14 to $36. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a confirmed uptrend — week 75 of stage 2. At $28.1 it trades +38.3% versus its 200-day average and sits at 65% of its 52-week range ($14–$36).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved −67% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Flotek Industries, Inc. trades at 28.5× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 28.5× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +147.1% against a +116.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Flotek Industries, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +26.3% | +19.7% | — | — |
| Profit | +200.0% | — | — | — |
| EPS | +147.1% | — | — | — |
| Stock price | +116.1% | +82.6% | +29.2% | −10.6% |
4-Factor Sector Score
67.9/100 — rank 2 of 30 in Oil & Gas Equipment & Services · 71% evidence confidence
Flotek Industries, Inc. scores 67.9 out of 100 against the 30 companies it is compared with in Oil & Gas Equipment & Services, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 26.2 + 12.3 + 10.5 + 18.9 = 67.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Flotek Industries, Inc. reported $0.1 B of revenue in the Mar 26 quarter, +16.7% year on year. That is the 6th straight quarter of year-on-year growth. Over 4 years it has compounded at 56.5% a year. The last full year, FY25, came in at $0.2 B. The last four reported quarters add to $0.3 B.
FY25 revenue came in at $0.2 B (+26.3% on the year), capping 4 years at 56.5% compound. The latest quarter (Mar 26) printed $0.1 B, +16.7% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +24.2% growth against the decade's 56.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +23.8% over the last 4 quarters against +20.2%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Flotek Industries, Inc.'s operating margin is 14.3% in the Mar 26 quarter, −2.4 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −75.0% to 10.5%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 14.3%, −2.4 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −75.0%–10.5%.
🚨 Why the margin moved: operating margin went −2.4 pp year on year while gross margin went +11.9 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Flotek Industries, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −100.0% year on year. Full-year FY25 profit was $0.0 B. That is 0.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, −100.0% year on year. On the full year, FY25 printed $0.0 B (+200.0%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 0% of Flotek Industries, Inc.'s reported profit arrived as operating cash — a gap worth watching. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash.
FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 0% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Flotek Industries, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Flotek Industries, Inc. earns a ROE of 27% in FY25. That is up from a trough of −150% in FY21. Return on invested capital clears the cost of that capital by +10.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.5% net margin on 1.09× asset turns.
FY25 ROE is 27%, recovered from a FY21 trough of −150% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 12.5% net margin × 1.09× asset turns × 2.00× balance-sheet leverage ≈ 27.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 22.1% − 12.1% = a +10.0 pp spread. The 12.1% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Flotek Industries, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Flotek Industries, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Flotek Industries, Inc. carries total debt of $0.1 B against shareholder equity of $0.1 B as of Mar 26, a debt-to-equity of 0.42. On the annual view that ratio went from 0.50 in FY21 to 0.45 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.1 B against shareholder equity of $0.1 B — a debt-to-equity of 0.42. On the annual view, debt-to-equity went from 0.50 (FY21) to 0.45 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
24.3% of Flotek Industries, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 4.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 24.3% of the float is sold short, and at typical trading volumes it would take about 4.4 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Flotek Industries, Inc.: the Z-score reads 2.72. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.72 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.72.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1TechnipFMC plcFTI | 68.1/100Favorable setup85% evidence | BREAKING OUT | 24.2/35 Revenue 9.9% · PAT 20.6% · OPM change 2.1 pp 95% evidence | 15.0/25 ROCE 9.8% · OPM 17.5% 76% evidence | 13.4/20 P/E 23× · PEG 0.64 65% evidence | 15.5/20 RS sector 4.4% · RS bench 12.7% · 1Y 84.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.2 + 15 + 13.4 + 15.5 = 68.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Flotek Industries, Inc.this pageFTK | 67.9/100Favorable setup71% evidence | TURNING | 26.2/35 Revenue 24.8% · PAT 100% · OPM change 0.7 pp 83% evidence | 12.3/25 ROCE 5.3% · OPM 10.8% 76% evidence | 10.5/20 P/E 21.8× · PEG — 15% evidence | 18.9/20 RS sector 24.5% · RS bench 36.5% · 1Y 116.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.2 + 12.3 + 10.5 + 18.9 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3National Energy Services Reunited Corp.NESR | 61.4/100Mixed-positive evidence81% evidence | LEADER | 19.5/35 Revenue 8.9% · PAT -15.6% · OPM change 2 pp 83% evidence | 10.6/25 ROCE 2.8% · OPM 8.9% 76% evidence | 13.9/20 P/E 33× · PEG 0.4 65% evidence | 17.4/20 RS sector 27.5% · RS bench 36.5% · 1Y 209.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 10.6 + 13.9 + 17.4 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Cactus, Inc.WHD | 60.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.9/35 Revenue — · PAT — · OPM change -11.8 pp 45% evidence | 14.4/25 ROCE 4.5% · OPM 12.7% 76% evidence | 9.6/20 P/E 43.8× · PEG — 15% evidence | 18.3/20 RS sector 9.3% · RS bench 19.7% · 1Y 70.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 14.4 + 9.6 + 18.3 = 60.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Tidewater Inc.TDW | 59.6/100Mixed-positive evidence81% evidence | BREAKING OUT | 13.6/35 Revenue -0.9% · PAT 69.7% · OPM change -4.4 pp 83% evidence | 12.6/25 ROCE 3.1% · OPM 18.1% 76% evidence | 15.0/20 P/E 14× · PEG 0.43 65% evidence | 18.4/20 RS sector 8.3% · RS bench 17.6% · 1Y 57.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 12.6 + 15 + 18.4 = 59.6 · Decision use: Price leads the evidence: RS versus the benchmark is 17.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Solaris Energy Infrastructure, Inc.SEI | 59.3/100Mixed-positive evidence81% evidence | ASLEEP | 26.7/35 Revenue 86.5% · PAT 100% · OPM change 8.3 pp 83% evidence | 12.9/25 ROCE 2.8% · OPM 25.8% 76% evidence | 13.0/20 P/E 63.5× · PEG 0.5 65% evidence | 6.7/20 RS sector -4% · RS bench 5.2% · 1Y 71.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 12.9 + 13 + 6.7 = 59.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -4% and the one-year return is 71.7%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Oceaneering International, Inc.OII | 58.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 15.6/35 Revenue — · PAT — · OPM change -2.6 pp 45% evidence | 12.5/25 ROCE 4.9% · OPM 8.3% 76% evidence | 11.5/20 P/E 11.6× · PEG — 15% evidence | 18.5/20 RS sector 16.8% · RS bench 26.2% · 1Y 91.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 12.5 + 11.5 + 18.5 = 58.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8USA Compression Partners, LPUSAC | 58.0/100Mixed-positive evidence81% evidence | TURNING | 22.8/35 Revenue 12.1% · PAT 34.4% · OPM change -0.7 pp 83% evidence | 14.7/25 ROCE 3% · OPM 27.6% 76% evidence | 13.0/20 P/E 28× · PEG 0.66 65% evidence | 7.5/20 RS sector -14.7% · RS bench -5.7% · 1Y 11.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 14.7 + 13 + 7.5 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9LandBridge Company LLCLB | 56.6/100Mixed-positive evidence64% evidence | BREAKING OUT | 17.6/35 Revenue 54.5% · PAT — · OPM change 0.2 pp 62% evidence | 11.8/25 ROCE 2.5% · OPM 57.2% 76% evidence | 9.3/20 P/E 71.2× · PEG — 15% evidence | 17.9/20 RS sector 5.1% · RS bench 15.4% · 1Y 61.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 11.8 + 9.3 + 17.9 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Archrock, Inc.AROC | 53.8/100Mixed-positive evidence81% evidence | ASLEEP | 21.2/35 Revenue 22.6% · PAT 60.1% · OPM change -1.3 pp 83% evidence | 15.6/25 ROCE 3.2% · OPM 33.8% 76% evidence | 15.0/20 P/E 18.9× · PEG 0.34 65% evidence | 2.0/20 RS sector -15.8% · RS bench -8.1% · 1Y 28.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 15.6 + 15 + 2 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Tenaris S.A.TS | 53.0/100Mixed-positive evidence85% evidence | ASLEEP | 12.6/35 Revenue 2.3% · PAT -3.3% · OPM change -2.2 pp 95% evidence | 17.6/25 ROCE 12.2% · OPM 16.7% 76% evidence | 13.0/20 P/E 14.6× · PEG 0.95 65% evidence | 9.8/20 RS sector -3.1% · RS bench 5.2% · 1Y 61.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 17.6 + 13 + 9.8 = 53 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Kodiak Gas Services, Inc.KGS | 47.8/100Mixed-negative evidence81% evidence | ASLEEP | 21.8/35 Revenue 3.9% · PAT 32.7% · OPM change 3.8 pp 83% evidence | 11.6/25 ROCE 2.6% · OPM 30.9% 76% evidence | 6.7/20 P/E 78.8× · PEG 1.99 65% evidence | 7.7/20 RS sector -3% · RS bench 4.4% · 1Y 75.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 11.6 + 6.7 + 7.7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Select Water Solutions, Inc.WTTR | 47.4/100Mixed-negative evidence64% evidence | TURNING | 15.1/35 Revenue -4.1% · PAT — · OPM change 0.7 pp 62% evidence | 5.5/25 ROCE 1.3% · OPM 4.9% 76% evidence | 9.1/20 P/E 72.9× · PEG — 15% evidence | 17.7/20 RS sector 18.2% · RS bench 27.9% · 1Y 103.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 5.5 + 9.1 + 17.7 = 47.4 · Decision use: Price leads the evidence: RS versus the benchmark is 27.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14NOV Inc.NOV | 46.7/100Thin evidence · provisional58% evidence | TURNING | 17.1/35 Revenue — · PAT — · OPM change -4.9 pp 45% evidence | 8.2/25 ROCE 2.2% · OPM 2.3% 76% evidence | 9.2/20 P/E 71.3× · PEG — 15% evidence | 12.2/20 RS sector -3.3% · RS bench 5.9% · 1Y 62.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 8.2 + 9.2 + 12.2 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Halliburton CompanyHAL | 46.3/100Mixed-negative evidence85% evidence | ASLEEP | 11.0/35 Revenue 0.6% · PAT -14.2% · OPM change -0.4 pp 95% evidence | 18.0/25 ROCE 14.9% · OPM 12.8% 76% evidence | 11.9/20 P/E 17.7× · PEG 1.08 65% evidence | 5.4/20 RS sector -10.9% · RS bench -2.8% · 1Y 53.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 18 + 11.9 + 5.4 = 46.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Flowco Holdings Inc.FLOC | 45.4/100Mixed-negative evidence71% evidence | ASLEEP | 19.1/35 Revenue 17.7% · PAT 45.6% · OPM change -1.1 pp 83% evidence | 12.1/25 ROCE 2.2% · OPM 17.3% 76% evidence | 10.9/20 P/E 17.6× · PEG — 15% evidence | 3.3/20 RS sector -15.2% · RS bench -7.2% · 1Y 34.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 12.1 + 10.9 + 3.3 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Enerflex Ltd.EFXT | 44.2/100Mixed-negative evidence81% evidence | ASLEEP | 16.3/35 Revenue 11.8% · PAT 12.2% · OPM change -1.3 pp 83% evidence | 11.0/25 ROCE 3.7% · OPM 11.6% 76% evidence | 6.8/20 P/E 31.3× · PEG 2.31 65% evidence | 10.1/20 RS sector 0.1% · RS bench 7.7% · 1Y 108.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11 + 6.8 + 10.1 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18SLB N.V.SLB | 42.4/100Mixed-negative evidence85% evidence | TURNING | 10.7/35 Revenue 2.5% · PAT -25.2% · OPM change -1.8 pp 95% evidence | 12.2/25 ROCE 2.8% · OPM 11.9% 76% evidence | 8.7/20 P/E 22.5× · PEG 1.89 65% evidence | 10.8/20 RS sector -4.2% · RS bench 4.5% · 1Y 51.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 12.2 + 8.7 + 10.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Innovex International, Inc.INVX | 41.9/100Mixed-negative evidence75% evidence | TURNING | 9.6/35 Revenue 26.4% · PAT -63.6% · OPM change -18.2 pp 83% evidence | 4.5/25 ROCE -2% · OPM -9.1% 76% evidence | 14.9/20 P/E 32.5× · PEG 0.1 65% evidence | 12.9/20 RS sector 0.4% · RS bench 10.1% · 1Y 69%4 of 12 weeks ahead 70% evidence |
| Exact sum: 9.6 + 4.5 + 14.9 + 12.9 = 41.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 20Bristow Group Inc.VTOL | 41.7/100Mixed-negative evidence75% evidence | ASLEEP | 14.1/35 Revenue 6.8% · PAT 0.9% · OPM change -0.7 pp 83% evidence | 7.5/25 ROCE 1.8% · OPM 8.9% 76% evidence | 16.1/20 P/E 12.2× · PEG 0.24 65% evidence | 4.0/20 RS sector -17.4% · RS bench -8.7% · 1Y 11.4%1 of 12 weeks ahead 70% evidence |
| Exact sum: 14.1 + 7.5 + 16.1 + 4 = 41.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21RPC, Inc.RES | 37.8/100Thin evidence · provisional52% evidence | ASLEEP | 15.9/35 Revenue — · PAT — · OPM change -3.1 pp 45% evidence | 7.9/25 ROCE 1.2% · OPM 0.6% 76% evidence | 9.4/20 P/E 64.8× · PEG — 15% evidence | 4.6/20 RS sector -15.8% · RS bench -7.5% · 1Y 32.6%0 of 12 weeks ahead 70% evidence |
| Exact sum: 15.9 + 7.9 + 9.4 + 4.6 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Weatherford International plcWFRD | 37.2/100Thin evidence · provisional58% evidence | ASLEEP | 13.4/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence | 11.2/25 ROCE 2.9% · OPM 10.7% 76% evidence | 11.1/20 P/E 16.1× · PEG — 15% evidence | 1.5/20 RS sector -20.4% · RS bench -12.7% · 1Y 29.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 11.2 + 11.1 + 1.5 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Baker Hughes CompanyBKR | 36.0/100Mixed-negative evidence85% evidence | ASLEEP | 12.2/35 Revenue 0.4% · PAT 1.3% · OPM change -0.6 pp 95% evidence | 12.9/25 ROCE 3% · OPM 14.2% 76% evidence | 6.0/20 P/E 17.9× · PEG 2.86 65% evidence | 4.9/20 RS sector -15% · RS bench -6.7% · 1Y 19%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 12.9 + 6 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Liberty Energy Inc.LBRT | 33.9/100Thin evidence · provisional58% evidence | ASLEEP | 17.2/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 6.8/25 ROCE 0.4% · OPM 2.2% 76% evidence | 9.7/20 P/E 35.4× · PEG — 15% evidence | 0.2/20 RS sector -27.2% · RS bench -21.3% · 1Y 75.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 6.8 + 9.7 + 0.2 = 33.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Expro Group Holdings N.V.XPRO | 33.9/100Thin evidence · provisional52% evidence | BREAKING OUT | 13.0/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 4.8/25 ROCE 0.6% · OPM 0.9% 76% evidence | 8.8/20 P/E 82.1× · PEG — 15% evidence | 7.3/20 RS sector -9.9% · RS bench -0.8% · 1Y 37%6 of 12 weeks ahead 70% evidence |
| Exact sum: 13 + 4.8 + 8.8 + 7.3 = 33.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26ProPetro Holding Corp.PUMP | 30.9/100Thin evidence · provisional52% evidence | ASLEEP | 14.8/35 Revenue — · PAT — · OPM change -5.6 pp 45% evidence | 4.2/25 ROCE -0.2% · OPM -3% 76% evidence | 8.6/20 P/E 951× · PEG — 15% evidence | 3.3/20 RS sector -24.4% · RS bench -18.5% · 1Y 110.5%0 of 12 weeks ahead 70% evidence |
| Exact sum: 14.8 + 4.2 + 8.6 + 3.3 = 30.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Atlas Energy Solutions Inc.AESI | 23.8/100Adverse evidence71% evidence | ASLEEP | 4.7/35 Revenue -8.3% · PAT -391.2% · OPM change -17.4 pp 83% evidence | 4.5/25 ROCE -1.6% · OPM -12.2% 76% evidence | 8.7/20 P/E 95.5× · PEG — 15% evidence | 5.9/20 RS sector -8% · RS bench 0.4% · 1Y 25%2 of 12 weeks ahead 100% evidence |
| Exact sum: 4.7 + 4.5 + 8.7 + 5.9 = 23.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28EagleRock Land, LLCEROK | 51.7/100Thin evidence · provisional21% evidence | BREAKING OUT | 18.0/35 Revenue — · PAT — · OPM change 18.2 pp 7% evidence | 13.7/25 ROCE 7.2% · OPM 40.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 6 weeks ahead 0% evidence |
| Exact sum: 18 + 13.7 + 10 + 10 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29WaterBridge Infrastructure LLCWBI | 47.5/100Thin evidence · provisional50% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change -0.9 pp 39% evidence | 9.6/25 ROCE 1.3% · OPM 15.2% 76% evidence | 8.5/20 P/E 1040.6× · PEG — 15% evidence | 11.4/20 RS sector -2.5% · RS bench 7.2% · 1Y 33.4%7 of 12 weeks ahead 70% evidence |
| Exact sum: 18 + 9.6 + 8.5 + 11.4 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30NextDecade CorporationNEXT | 42.6/100Thin evidence · provisional47% evidence | BASING | 17.9/35 Revenue — · PAT — · OPM change — 33% evidence | 5.5/25 ROCE -0.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.2/20 RS sector -10.1% · RS bench -1% · 1Y 7.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 5.5 + 10 + 9.2 = 42.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Flotek Industries, Inc.'s stock price today?
Flotek Industries, Inc. trades at $28.1, +116.1% over the past year. The company is valued at $1.0 B. The stock sits at 65% of its 52-week range of $14–$36, +38.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 75 weeks in. — as of 17 September 2026.
What were Flotek Industries, Inc.'s latest quarterly results?
Flotek Industries, Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 16.7% and profit fell 100.0% year on year. Earnings per share were $0.12. The operating margin was 14.3%, 2.4 pp lower than a year earlier. — as of 17 September 2026.
What is Flotek Industries, Inc.'s revenue?
Flotek Industries, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +16.7% year on year. For the full FY25 fiscal year, revenue was $0.2 B (+26.3%). Over the last 4 years revenue compounded at 56.5% a year. — as of 17 September 2026.
What is Flotek Industries, Inc.'s profit?
Flotek Industries, Inc. earned $0.0 B of net profit in the Mar 26 quarter, −100.0% year on year. Full-year FY25 profit was $0.0 B. The operating margin ran 14.3% in the latest quarter. — as of 17 September 2026.
What is Flotek Industries, Inc.'s market cap?
Flotek Industries, Inc.'s market capitalisation is $1.0 B at a stock price of $28.1. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does Flotek Industries, Inc. pay a dividend?
No — Flotek Industries, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Flotek Industries, Inc. growing?
Not right now — Flotek Industries, Inc.'s latest numbers are shrinking: latest-quarter revenue +16.7% year on year, profit −100.0%, and the margin −2.4 pp at 14.3%. The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Flotek Industries, Inc. performing?
Flotek Industries, Inc. is in a confirmed uptrend, 75 weeks in. Its latest quarter's revenue rose 16.7% and profit fell 100.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Flotek Industries, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 75 of stage 2), trading +38.3% versus its 200-day average and at 65% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Flotek Industries, Inc. beating the market?
On recent form, yes — Flotek Industries, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved −67% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will Flotek Industries, Inc.'s stock price go up?
This page publishes no price forecast for Flotek Industries, Inc. What it measures instead: the stock price is $28.1, the price is in a confirmed uptrend 75 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Flotek Industries, Inc.?
Yes — short interest is 24.3% of Flotek Industries, Inc.'s tradable float, about 4.4 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Flotek Industries, Inc. have too much debt?
It is moderate — Flotek Industries, Inc.'s debt-to-equity is 0.44. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Flotek Industries, Inc.'s capex?
Flotek Industries, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Flotek Industries, Inc.'s cash flow?
Flotek Industries, Inc. generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran behind profit. — as of 17 September 2026.
Is Flotek Industries, Inc.'s profit real cash?
Not fully — over the last 3 fiscal years, 0% of Flotek Industries, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.0 B against reported profit of $0.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Flotek Industries, Inc.?
On the balance sheet, the Z-score reads 2.72 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 17 September 2026.
Where is Flotek Industries, Inc. in its business cycle?
Flotek Industries, Inc.'s FY25 operating margin was 8.3%, against a 5-year band of −75.0%–10.5%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 14.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Flotek Industries, Inc. story?
The sharpest disagreement: annual EPS moved +147.1% against a +116.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Flotek Industries, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Flotek Industries, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!